6 results about "Reserpine" patented technology

The invention belongs to the technical field of experimental animals, and particularly relates to application of reserpine in construction of animal models with normal high and low density lipoprotein and triglyceride values. The animal model construction method is minimally invasive, low in cost and good in reproducibility, has remarkable western medicine clinical biochemical index characteristics and a clear action mechanism, and can successfully and repeatedly establish an animal model with high and low density lipoprotein and normal triglyceride values. Conditions are created for clinical research on pathogenesis of related diseases, diagnosis and treatment of related diseases and screening, research and treatment of related disease mechanisms and drugs thereof, and good application prospects are achieved.

The present application relates to a hybridoma cell strain secreting anti-reserpine monoclonal antibody and its application, and belongs to the technical field of drug safety immune detection. The hybridoma cell strain secreting anti-monoclonal antibody has been preserved in the China General Microbiological Culture Collection Center on April 17, 2025, with a preservation number of CGMCC No. 46508, a preservation address of No. 3, Xibaixili, Chaoyang District, Beijing, and a classification designation of monoclonal cell strain. The reserpine monoclonal antibody cell strain obtained by the present application can be used for reserpine analysis and detection in drugs and food, has good detection sensitivity (IC 50 value of 0.579 ng / mL) and specificity (cross rate of less than 1% for related structural analogues), can realize the detection of reserpine in drugs, can assist clinical diagnosis, and has practical application value.

The invention relates to a hybridoma cell strain secreting an anti-reserpine monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of drug safety immunodetection. The hybridoma cell strain secreting the anti-monoclonal antibody is preserved in the China General Microbiological Culture Collection Center on April 17, 2025, the preservation number is CGMCC No.46508, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the hybridoma cell strain is classified and named as a monoclonal cell strain. The reserpine monoclonal antibody cell strain obtained by the invention can be used for analyzing and detecting reserpine in drugs and food, has better detection sensitivity (IC50 value is 0.579 ng / mL) and specificity (the cross-over rate for related structural analogues is less than 1%) on reserpine, can realize detection on reserpine in drugs, can assist clinical diagnosis, and has practical application value.

The invention provides application of calculus bovis in preparation of an anti-depression product, and belongs to the technical field of medicines. The invention provides application of calculus bovis in preparation of an anti-depression product. Reserpine and CUMS depression mouse models are used, it is verified that ICCB can remarkably improve depression-like characterization of two animal models of reserpine and CUMS, it is proved for the first time that ICCB has the anti-depression effect, meanwhile, pathological damage of hippocampal neurons of mice after modeling can be effectively inhibited, various indexes of the liver function of the model mice can be remarkably recovered, and the ICCB has the anti-depression effect. The ICCB has the effect of regulating the blood fat level remarkably related to liver metabolism, and particularly has the effect of regulating the blood fat level remarkably related to liver metabolism, so that the ICCB not only improves depression-like characterization and pathological damage of two animal models of reserpine and CUMS, but also has a certain protection effect on liver functions and blood fat metabolism functions which are reduced after modeling.

The invention relates to the technical field of biological medicine, and discloses a co-crystal medicine ZM889 and application thereof in lung cancer resistance, a preparation method of the co-crystal medicine ZM889 comprises the following steps: mixing osimertinib, reserpine and a mixed solvent, heating, stirring and dissolving, then adding n-hexane, and separating out a yellow solid, namely the co-crystal medicine ZM889. The antitumor activity of the eutectic molecule ZM889 disclosed by the invention is enhanced compared with that of a non-eutectic counterpart of the eutectic molecule ZM889; in an in-vitro experiment, the eutectic drug ZM889 shows a remarkable inhibition effect on an osimertinib drug-resistant cell strain. According to the eutectic medicine ZM889 and the preparation method thereof, a new strategy is provided for the field of anti-lung cancer treatment.

A method for making a sulfur cathode, comprising steps oF mixing sulfur and an amount of a purine compound in a weight ratio of sulfur to purine of from less than 10:1 to greater than 2:1 to form a powder mixture; mixing the powder mixture with a solvent to form a slurry; and drying the slurry onto a current collector to form the sulfur cathode. A cathode for use in a lithium sulfur battery including sulfur; and an purine selected from the group consisting of caffeine, nicotine, morphine, codeine, quinine, atropine, ephedrine, strychnine, colchicine, theobromine, theophylline, papaverine, reserpine, coniine, harmine, ibogaine, vinblastine, vincristine, yohimbine, capsaicin, camptothecin, mitragynine, apomorphine, psilocybin, scopolamine, tetrahydrocannabinol (THC), salvinorin A, mescaline, muscarine, preferably, the purine is caffeine. Also disclosed are electrolytes and batteries.